Rapt Therapeutics (NASDAQ:RAPT) Receives Consensus Recommendation of “Hold” from Analysts

Shares of Rapt Therapeutics (NASDAQ:RAPT) have been given a consensus recommendation of “Hold” by the thirteen analysts that are presently covering the company, MarketBeat.com reports. One analyst has rated the stock with a sell recommendation, ten have issued a hold recommendation, one has issued a buy recommendation and one has issued a strong buy recommendation on the company. The average twelve-month price objective among brokers that have issued a report on the stock in the last year is $48.4444.

A number of analysts have issued reports on the company. HC Wainwright downgraded Rapt Therapeutics from a “buy” rating to a “neutral” rating and set a $58.00 target price for the company. in a research note on Tuesday, January 20th. Clear Str lowered shares of Rapt Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Tuesday, January 20th. Barclays downgraded shares of Rapt Therapeutics from an “overweight” rating to an “equal weight” rating and set a $58.00 target price on the stock. in a research note on Wednesday, January 21st. Weiss Ratings reissued a “sell (d-)” rating on shares of Rapt Therapeutics in a research note on Thursday, January 22nd. Finally, TD Cowen downgraded shares of Rapt Therapeutics from a “buy” rating to a “hold” rating in a report on Tuesday, January 20th.

Institutional Investors Weigh In On Rapt Therapeutics

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Susquehanna International Group LLP raised its holdings in Rapt Therapeutics by 173.4% in the 3rd quarter. Susquehanna International Group LLP now owns 45,382 shares of the company’s stock valued at $1,170,000 after buying an additional 28,782 shares during the period. Millennium Management LLC boosted its stake in Rapt Therapeutics by 75.2% during the third quarter. Millennium Management LLC now owns 39,278 shares of the company’s stock worth $1,013,000 after buying an additional 16,854 shares during the period. Ameriprise Financial Inc. acquired a new stake in shares of Rapt Therapeutics during the third quarter valued at about $1,326,000. Bridgeway Capital Management LLC raised its stake in shares of Rapt Therapeutics by 32.0% in the 3rd quarter. Bridgeway Capital Management LLC now owns 20,625 shares of the company’s stock valued at $532,000 after acquiring an additional 5,000 shares during the period. Finally, UBS Group AG lifted its holdings in shares of Rapt Therapeutics by 680.3% in the 3rd quarter. UBS Group AG now owns 28,808 shares of the company’s stock worth $743,000 after acquiring an additional 25,116 shares during the last quarter. Hedge funds and other institutional investors own 99.09% of the company’s stock.

Rapt Therapeutics Trading Up 0.0%

RAPT stock opened at $57.69 on Friday. The firm has a 50-day moving average of $40.61 and a two-hundred day moving average of $27.98. Rapt Therapeutics has a 12 month low of $5.67 and a 12 month high of $57.86. The company has a market cap of $1.60 billion, a price-to-earnings ratio of -5.22 and a beta of 0.47.

Rapt Therapeutics (NASDAQ:RAPT) last posted its quarterly earnings results on Thursday, November 6th. The company reported ($0.65) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.88) by $0.23. As a group, equities analysts forecast that Rapt Therapeutics will post -2.14 earnings per share for the current year.

Rapt Therapeutics Company Profile

RAPT Therapeutics, Inc (NASDAQ:RAPT) is a clinical-stage biotechnology company developing novel therapeutics for autoimmune and allergic diseases. Founded in 2013 and headquartered in San Diego, California, RAPT applies tissue-selective immunology to design small molecule and biologic candidates that modulate immune cell trafficking and tissue-resident pathways. The company’s research platform enables the identification of targets that drive tissue inflammation with the goal of achieving improved efficacy and safety profiles over current therapies.

The company’s lead asset, RPT193, is an orally available antagonist of the CC chemokine receptor 4 (CCR4), currently in clinical development for atopic dermatitis and allergic asthma.